{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:50:51Z","timestamp":1787237451765,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM067100"],"award-info":[{"award-number":["GM067100"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Stress and Chaperones"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.cstres.2024.08.002","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T17:22:04Z","timestamp":1724433724000},"page":"642-653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials"],"prefix":"10.1016","volume":"29","author":[{"given":"Cheng","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Woodley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cstres.2024.08.002_bib1","unstructured":"U.S. FDA, Oncology (Cancer) \/ Hematologic Malignancies Approval Notifications. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancer-hematologic-malignancies-approval-notifications. Accessed April 17, 2024."},{"key":"10.1016\/j.cstres.2024.08.002_bib2","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2174\/156802609789895728","article-title":"Update on Hsp90 inhibitors in clinical trial","volume":"9","author":"Kim","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.cstres.2024.08.002_bib3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cstres.2024.08.002_bib4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.bbamcr.2011.10.008","article-title":"Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers","volume":"1823","author":"Jhaveri","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cstres.2024.08.002_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","article-title":"Hsp90 molecular chaperone inhibitors: are we there yet?","volume":"18","author":"Neckers","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cstres.2024.08.002_bib6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.breast.2013.06.003","article-title":"Hsp90 inhibitors in breast cancer: a systematic review","volume":"22","author":"Zagouri","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.cstres.2024.08.002_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/978-1-4939-7477-1_29","article-title":"Clinical evaluation and biomarker profiling of Hsp90 inhibitors","volume":"1709","author":"Yuno","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.cstres.2024.08.002_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s12192-018-0877-2","article-title":"Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development","volume":"23","author":"Neckers","year":"2018","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.cstres.2024.08.002_bib9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/1568009619666191202101330","article-title":"Old and new approaches to target the Hsp90 chaperone","volume":"20","author":"Sanchez","year":"2020","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.cstres.2024.08.002_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-3-030-40204-4_9","article-title":"The right tool for the job: an overview of Hsp90 inhibitors","volume":"1243","author":"Koren","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.cstres.2024.08.002_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2147763","article-title":"Heat shock protein 90 (HSP90) inhibitors as anticancer medicines: a review on the computer-aided drug discovery approaches over the past five years","volume":"2022","author":"Magwenyane","year":"2022","journal-title":"Comput Math Methods Med"},{"key":"10.1016\/j.cstres.2024.08.002_bib12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cstres.2024.05.005","article-title":"An update on the status of HSP90 inhibitors in cancer clinical trials","volume":"29","author":"Rastogi","year":"2024","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.cstres.2024.08.002_bib13","unstructured":"Taiho Pharmaceutical Obtains Approval to Manufacture and Market HSP90 inhibitor Jeselhy\u00ae Tablets 40 mg (Pimitespib) for Gastrointestinal Stromal Tumor (GIST). Available at: https:\/\/www.taiho.co.jp\/en\/release\/2022\/20220620.html#:~:text=announced%20today%20that%20it%20has,gastrointestinal%20stromal%20tumor%20(GIST)%20that. Accessed June 20, 2022."},{"key":"10.1016\/j.cstres.2024.08.002_bib14","unstructured":"The Human Protein Atlas. Available at:\u00a0https:\/\/www.proteinatlas.org\/search\/Hsp90.\u00a0Accessed May 30,\u00a02024."},{"key":"10.1016\/j.cstres.2024.08.002_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/cells12020277","article-title":"The distinct assignments for Hsp90alpha and Hsp90beta: more than skin deep","volume":"12","author":"Chang","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.cstres.2024.08.002_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1242\/dev.127.1.1","article-title":"Mice lacking HSP90beta fail to develop a placental labyrinth","volume":"127","author":"Voss","year":"2000","journal-title":"Development"},{"key":"10.1016\/j.cstres.2024.08.002_bib17","article-title":"The molecular chaperone Hsp90\u03b1 is required for meiotic progression of spermatocytes beyond pachytene in the mouse","volume":"5","author":"Grad","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cstres.2024.08.002_bib18","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/genetics\/151.3.1065","article-title":"Genetic analysis of viable Hsp90 alleles reveals a critical role in Drosophila spermatogenesis","volume":"151","author":"Yue","year":"1999","journal-title":"Genetics"},{"key":"10.1016\/j.cstres.2024.08.002_bib19","doi-asserted-by":"crossref","first-page":"16363","DOI":"10.1073\/pnas.1108372108","article-title":"Heat shock protein 90 (Hsp90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells","volume":"108","author":"Imai","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cstres.2024.08.002_bib20","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1242\/bio.2012646","article-title":"Spermatogenesis arrest caused by conditional deletion of Hsp90\u03b1 in adult mice","volume":"1","author":"Kajiwara","year":"2012","journal-title":"Biol Open"},{"key":"10.1016\/j.cstres.2024.08.002_bib21","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/s41417-021-00316-6","article-title":"Heat shock protein-90alpha (Hsp90\u03b1) stabilizes hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) in support of spermatogenesis and tumorigenesis","volume":"28","author":"Tang","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.cstres.2024.08.002_bib22","first-page":"1227","article-title":"EPAS1 is required for spermatogenesis in the postnatal mouse testis","volume":"82","author":"Gruber","year":"2010","journal-title":"Biol\u00a0Reprod"},{"key":"10.1016\/j.cstres.2024.08.002_bib23","article-title":"Hypoxia inducible factor 1 alpha is expressed in germ cells throughout the murine life cycle","volume":"1","author":"Takahashi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cstres.2024.08.002_bib24","first-page":"234","article-title":"Isoform-specific expression of hypoxia-inducible factor-1alpha during the late stages of mouse spermiogenesis","volume":"16","author":"Marti","year":"2002","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.cstres.2024.08.002_bib25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1095\/biolreprod.104.027797","article-title":"A dominant-negative isoform of hypoxia-inducible factor-1 alpha specifically expressed in human testis","volume":"71","author":"Depping","year":"2004","journal-title":"Biol Reprod"},{"key":"10.1016\/j.cstres.2024.08.002_bib26","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.4049\/jimmunol.178.10.6100","article-title":"Involvement of heat shock protein (Hsp)90 beta but not Hsp90 alpha in antiapoptotic effect of CpG-B oligodeoxynucleotide","volume":"178","author":"Kuo","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.cstres.2024.08.002_bib27","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.molcel.2009.07.023","article-title":"Characterization of cytoplasmic caspase-2 activation by induced proximity","volume":"35","author":"Bouchier-Hayes","year":"2009","journal-title":"Mol Cell"},{"key":"10.1016\/j.cstres.2024.08.002_bib28","doi-asserted-by":"crossref","first-page":"7451","DOI":"10.4049\/jimmunol.0804296","article-title":"HSP90alpha and HSP90beta isoforms selectively modulate MHC class II antigen presentation in B cells","volume":"182","author":"Houlihan","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.cstres.2024.08.002_bib29","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3324\/haematol.2012.066175","article-title":"The PI3K\/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma","volume":"98","author":"Chatterjee","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.cstres.2024.08.002_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1139\/O07-154","article-title":"A comparison of Hsp90alpha and Hsp90beta interactions with cochaperones and substrates","volume":"86","author":"Taherian","year":"2008","journal-title":"Biochem Cell Biol"},{"key":"10.1016\/j.cstres.2024.08.002_bib31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1159\/000322333","article-title":"Opposite effect of Hsp90\u03b1 and Hsp90\u03b2 on eNOS ability to produce nitric oxide or superoxide anion in human embryonic kidney cells","volume":"26","author":"Cortes-Gonz\u00e1lez","year":"2010","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.cstres.2024.08.002_bib32","article-title":"Distinct roles of molecular chaperones HSP90\u03b1 and HSP90\u03b2 in the biogenesis of KCNQ4 channels","volume":"8","author":"Gao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cstres.2024.08.002_bib33","first-page":"1475","article-title":"Hsp90\u03b1 and Hsp90\u03b2 together operate a hypoxia and nutrient paucity stress-response mechanism during wound healing","volume":"128","author":"Jayaprakash","year":"2015","journal-title":"J Cell Sci"},{"key":"10.1016\/j.cstres.2024.08.002_bib34","doi-asserted-by":"crossref","first-page":"1700386","DOI":"10.1183\/13993003.00386-2017","article-title":"Synergistic role of HSP90\u03b1 and HSP90\u03b2 to promote myofibroblast persistence in lung fibrosis","volume":"51","author":"Bellaye","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cstres.2024.08.002_bib35","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/onc.2016.375","article-title":"Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression","volume":"36","author":"Zou","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.cstres.2024.08.002_bib36","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/humu.9141","article-title":"Molecular variation of human HSP90alpha and HSP90beta genes in Caucasians","volume":"21","author":"Passarino","year":"2003","journal-title":"Hum Mutat"},{"key":"10.1016\/j.cstres.2024.08.002_bib37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10930-008-9160-1","article-title":"Single nucleotide polymorphism that accompanies a missense mutation (Gln488His) impedes the dimerization of Hsp90","volume":"28","author":"Kobayakawa","year":"2009","journal-title":"Protein J"},{"key":"10.1016\/j.cstres.2024.08.002_bib38","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1091\/mbc.e11-06-0575","article-title":"A potentially common peptide target in secreted heat shock protein-90\u03b1 for hypoxia-inducible factor-1\u03b1-positive tumors","volume":"23","author":"Sahu","year":"2012","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.cstres.2024.08.002_bib39","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s12192-013-0413-3","article-title":"Proteomic data from human cell cultures refine mechanisms of chaperone-mediated protein homeostasis","volume":"18","author":"Finka","year":"2013","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.cstres.2024.08.002_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/mcb.00459-21","article-title":"Heterogeneous responses and isoform compensation the dim therapeutic window of Hsp90 ATP-binding inhibitors in cancer","volume":"42","author":"Tang","year":"2022","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.cstres.2024.08.002_bib41","doi-asserted-by":"crossref","first-page":"22796","DOI":"10.1074\/jbc.271.37.22796","article-title":"Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin","volume":"271","author":"Mimnaugh","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cstres.2024.08.002_bib42","doi-asserted-by":"crossref","first-page":"14536","DOI":"10.1073\/pnas.93.25.14536","article-title":"Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90","volume":"93","author":"Schneider","year":"1996","journal-title":"Proc Natl Acad Sci\u00a0USA"},{"key":"10.1016\/j.cstres.2024.08.002_bib43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature01913","article-title":"A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors","volume":"425","author":"Kamal","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.cstres.2024.08.002_bib44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2174\/1568009033481778","article-title":"Development of purine-scaffold small molecule inhibitors of Hsp90","volume":"3","author":"Chiosis","year":"2003","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.cstres.2024.08.002_bib45","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1021\/jm049012b","article-title":"Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90","volume":"48","author":"Llauger","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.cstres.2024.08.002_bib46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1021\/jm0508078","article-title":"Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90","volume":"49","author":"He","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.cstres.2024.08.002_bib47","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.chembiol.2004.04.008","article-title":"Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90","volume":"11","author":"Vilenchik","year":"2004","journal-title":"Chem Biol"},{"key":"10.1016\/j.cstres.2024.08.002_bib48","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1359-6446(04)03245-3","article-title":"Hsp90: the vulnerable chaperone","volume":"9","author":"Chiosis","year":"2004","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.cstres.2024.08.002_bib49","doi-asserted-by":"crossref","first-page":"11099","DOI":"10.1074\/jbc.REV120.011833","article-title":"Post-translational modifications of Hsp90 and translating the chaperone code","volume":"295","author":"Backe","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cstres.2024.08.002_bib50","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002800050817","article-title":"The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin","volume":"42","author":"Schulte","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cstres.2024.08.002_bib51","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/mc.20141","article-title":"Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth","volume":"45","author":"Premkumar","year":"2006","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.cstres.2024.08.002_bib52","first-page":"161","article-title":"High anti-tumor activity against rhabdomyosarcoma cells and low normal cells cytotoxicity of heat shock protein 90 inhibitors, with special emphasis on 17-[2-(pyrrolidin-1-yl)ethyl]-aminno-17-demethoxygeldanamycin","volume":"60","author":"Lukasiewicz","year":"2009","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.cstres.2024.08.002_bib53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1021\/jm0508078","article-title":"Identification of potent water-soluble purine-scaffold inhibitors of the heat shock protein 90","volume":"49","author":"He","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.cstres.2024.08.002_bib54","first-page":"986","article-title":"17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2\/neu and inhibits the growth of prostate cancer xenografts","volume":"8","author":"Solit","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.cstres.2024.08.002_bib55","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1167\/iovs.07-1305","article-title":"17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines","volume":"49","author":"Babchia","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.cstres.2024.08.002_bib56","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1073\/pnas.91.18.8324","article-title":"Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation","volume":"91","author":"Whitesell","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cstres.2024.08.002_bib57","doi-asserted-by":"crossref","first-page":"24951","DOI":"10.1074\/jbc.M211600200","article-title":"Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK\/ERKM","volume":"278","author":"Calabrese","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cstres.2024.08.002_bib58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1476-4598-9-77","article-title":"Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells","volume":"9","author":"Cheung","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.cstres.2024.08.002_bib59","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3390\/cells11060976","article-title":"Hsp90 in human diseases: molecular mechanisms to therapeutic approaches","volume":"11","author":"Sumi","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.cstres.2024.08.002_bib60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.drudis.2007.10.007","article-title":"Development and application of Hsp90 inhibitors","volume":"13","author":"Solit","year":"2006","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.cstres.2024.08.002_bib61","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1535-7163.MCT-18-0831","article-title":"First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors","volume":"18","author":"Shimomura","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cstres.2024.08.002_bib62","first-page":"507","article-title":"Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors","volume":"20","author":"Toshihiko","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.cstres.2024.08.002_bib63","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11523-017-0490-9","article-title":"Novel insights into the treatment of imatinib-resistant gastrointestinal stromal tumors","volume":"12","author":"Serrano","year":"2017","journal-title":"Target Oncol"}],"container-title":["Cell Stress and Chaperones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1355814524001135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1355814524001135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:29:04Z","timestamp":1778801344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1355814524001135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1355814524001135"],"URL":"https:\/\/doi.org\/10.1016\/j.cstres.2024.08.002","relation":{},"ISSN":["1355-8145"],"issn-type":[{"value":"1355-8145","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials","name":"articletitle","label":"Article Title"},{"value":"Cell Stress and Chaperones","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cstres.2024.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of Cell Stress Society International.","name":"copyright","label":"Copyright"}]}}